FLT3 and neoplasm: The observation that potentially druggable mutations, such as FLT3 ITD, are commonly lost at relapse may be interpreted as supporting the exploration of maintenance strategies which utilise drug or cellular therapies with broader anti‐tumour specificity as opposed to targeted therapies.